Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03569371
Other study ID # INCB 54707-202
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date July 17, 2018
Est. completion date April 22, 2019

Study information

Verified date September 2022
Source Incyte Corporation
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess the safety of INCB054707 in men and women with moderate to severe hidradenitis suppurativa (HS).


Recruitment information / eligibility

Status Completed
Enrollment 10
Est. completion date April 22, 2019
Est. primary completion date April 22, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Diagnosis of HS (confirmed by a dermatologist) with a disease duration of at least 6 months before screening. - Stable course of HS for at least 90 days before screening, as determined by the investigator. - HS lesions present in at least 2 distinct anatomic areas, 1 of which must be Hurley Stage II or III at screening and baseline. - Total AN count of at least 3 at screening and baseline. - Male participants must agree to use contraception per protocol-defined criteria. Exclusion Criteria: - Women of childbearing potential or who are currently pregnant or lactating. - Presence of > 20 draining fistulas at screening and baseline. - Participants with concurrent conditions or history of other diseases as follows: - Any clinically significant medical condition other than HS, as determined by the investigator, that is not adequately controlled with appropriate treatment. - Any other active skin disease or condition (eg, bacterial, fungal, or viral infection) that may interfere with the course, severity, or assessments of HS. - Active systemic viral infection or any active viral infection that, based on the investigator's clinical assessment, make the participant an unsuitable candidate for the study. - Current herpes zoster infection, a history of recurrent herpes zoster, a history of disseminated herpes simplex, or a history of herpes zoster. - History of malignancy, including lymphoma and leukemia within 5 years before baseline, other than a successfully treated nonmetastatic cutaneous squamous cell carcinoma, basal cell carcinoma, or localized carcinoma in situ of the cervix. - Albinism. - Prolonged QT interval corrected for heart rate using Fridericia's formula (QTcF), defined as = 450 msec. - Positive test result for tuberculosis (TB) from the QuantiFERON-TB Gold test, or equivalent, at screening (or, if 2 indeterminate tests or not available, then as evaluated by a purified protein derivative test with a result of < 5 mm of induration within 3 months of screening) or a history of active TB. - Positive serology test results for HIV, HBsAg, hepatitis B virus (HBV) core antibody, or HCV (HCV antibody with positive HCV-RNA) at screening. - Decreased blood cell counts at screening as per protocol-defined parameters. - Severely impaired liver function (Child-Pugh Class C) or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels = 1.5 × upper limit of normal (ULN). - Impaired renal function with serum creatinine > 1.5 mg/dL. - Use of prohibited medications per protocol-defined criteria. - Known or suspected allergy to INCB054707 or any component of the study drug. - Known history of clinically significant drug or alcohol abuse in the last year prior to baseline. - Any condition that would, in the investigator's judgment, interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
INCB054707
INCB054707 administered once daily orally with water without regard to food for 8 weeks.

Locations

Country Name City State
United States Investigative Site Hershey Pennsylvania
United States Investigative Site Los Angeles California
United States Investigative Site New York New York
United States Investigative Site Tampa Florida

Sponsors (1)

Lead Sponsor Collaborator
Incyte Corporation

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With Treatment-emergent Adverse Events (TEAEs) A TEAE is any adverse event (AE) either reported for the first time or worsening of a pre-existing event after first dose of study drug. Up to approximately 12 weeks.
Secondary Apparent Oral Clearance of INCB054707(CL/F) To evaluate the systemic exposure to INCB054707. Postdose Day1, week 2 and 6
Secondary Apparent Oral Volume of Distribution of INCB054707(Vc/F) To evaluate the systemic exposure to INCB054707. Postdose Day1, week 2 and 6.
Secondary Absorption Constant of INCB054707 (Ka) Other population pharmacokinetic (PK) model parameter that the PK model may include to evaluate the systemic exposure to INCB054707. Postdose Day1, week 2 and 6.
Secondary Apparent Inter-compartmental Clearance(Q/F) Other population PK model parameter that the PK model may include to evaluate the systemic exposure to INCB054707. Postdose Day1, week 2 and 6.
Secondary Proportion of Participants With a Hidradenitis Suppurativa Clinical Response (HiSCR) at Each Visit An HiSCR is defined as at least 50% reduction in abscess and inflammatory nodule (AN) count with no increase in abscess count and no increase in draining fistula count relative to baseline at each visit. Weeks 1,2,4,6,8 and FollowUp
Secondary Proportion of Participants Achieving an AN Count of 0 to 2 at Each Visit The number and proportion of participants who achieved an Abscess and Inflammatory nodule count of 0 to 2 progressively. Weeks 1,2,4,6,8 and FollowUp
Secondary Mean Change From Baseline in the HS Pain Numeric Rating Scale (NRS) Scores at Each Visit The HS Pain NRS will be completed in a daily diary by participants from screening through EOS. An 11-point scale will be used to assess the worst skin pain due to HS based on a recall period of the last 24 hours. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine) Weeks 1,2,4,6,8 and FollowUp
Secondary Mean Change From Baseline in the Modified Sartorius Scale Score The Sartorius Scale is used to quantify the severity of HS. Points are awarded for 12 body areas (left and right axillae, left and right sub/inframammary areas, intermammary area, left and right buttocks, left and right inguino-crural folds, perianal area, perineal area, and other). For each area, points are awarded for nodules (2 points for each); abscesses (4 points); fistulas (4 points); scars (1 point); longest distance between two lesions (2-6 points, 0 if no lesions); and if lesions are separated buy normal skin (yes-0 point; no-6 points). The total Sartorius Scale score is the sum of the 12 regional scores. Scale scores range from 0 to infinite, with larger scores representing higher severity of HS. Week 8.
Secondary Mean Change From Baseline in the Number of Draining Fistulas Count at Each Visit Draining fistulas are fistulas that drain serous or purulent fluid, either spontaneously or by gentle palpation. Up to approximately 12 weeks.
Secondary Proportion of Participants at Each Category of Hurley Stage The Hurley classification is a static score and was originally designed for selection of the appropriate treatment modality in a certain body region. The assessor determines the Hurley stage in each affected anatomical region. If more than 1 stage is present in the same region, the worst stage in that region is documented. The participant will be assigned an overall Hurley stage classification corresponding to the stage of the worst involved anatomical region. The definition of each Hurley stage is as follows:
Stage I : Abscess formation, single or multiple, without sinus tracts and cicatrization (scarring).
Stage II : One or more widely separated recurrent abscesses with tract formation and cicatrization (scarring).
Stage III : Multiple interconnected tracts and abscesses across the entire area, with diffuse or near diffuse involvement.
Baseline and Week 8.
Secondary Proportion of Participants With Change From Baseline to Week 8 in Hurley Stage The Hurley classification is a static score and was originally designed for selection of the appropriate treatment modality in a certain body region. The assessor determines the Hurley stage in each affected anatomical region. If more than 1 stage is present in the same region, the worst stage in that region is documented. The participant will be assigned an overall Hurley stage classification corresponding to the stage of the worst involved anatomical region. The definition of each Hurley stage is as follows:
Stage I : Abscess formation, single or multiple, without sinus tracts and cicatrization (scarring).
Stage II : One or more widely separated recurrent abscesses with tract formation and cicatrization (scarring).
Stage III : Multiple interconnected tracts and abscesses across the entire area, with diffuse or near diffuse involvement.
Week 8.
Secondary Proportions of Participants in Each HS Patient Global Impression of Change (PGIC) Category The HS-PGIC consists of 1 self-administered item that assesses change in the severity of skin in the HS area. The participant will answer the following: Since your last visit, your HS is: (1) very much improved, (2) much improved, (3) minimally improved, (4) no change, (5) minimally worse, (6) much worse, or (7) very much worse. Up to approximately 12 weeks.
Secondary Proportion of Participants Requiring Rescue Lesional Treatment Rescue lesional treatment is defined as immediate intervention in the event of an acutely painful lesion. Up to approximately 12 weeks.
Secondary Number of Interventions With Rescue Lesional Treatment Rescue lesional treatment is defined as immediate intervention in the event of an acutely painful lesion. Up to approximately 12 weeks.
Secondary Proportion of Participants at Each Scoring Category of the Dermatology Life Quality Index (DLQI) at Each Visit The DLQI is a questionnaire used to assess the symptoms and the impact of skin problems on quality of life. The DLQI is calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The meaning of DLQI scores can be categorized as follows: 0-1 = No effect at all on patient's life 2-5 = Small effect on patient's life 6-10 = Moderate effect on patient's life 11-20 = Very large effect on patient's life 21-30 = Extremely large effect on patient's life Up to approximately 12 weeks.
See also
  Status Clinical Trial Phase
Completed NCT02904902 - Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis Suppurativa Phase 3
Completed NCT03628924 - A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS) Phase 2
Not yet recruiting NCT05531747 - Replicative Stress in Hair Follicle Stem Cells and Pathogeny of Hidradenitis Suppurativa N/A
Recruiting NCT06028230 - A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Phase 2
Completed NCT03275870 - Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa Phase 1/Phase 2
Completed NCT03248531 - A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa. Phase 2
Withdrawn NCT04100083 - Spironolactone for Hidradenitis Suppurativa Phase 4
Completed NCT00329823 - Etanercept in Hidradenitis Suppurativa Phase 2
Recruiting NCT05710393 - Hidradenitis - an Analysis of Genetic Traits and Linkages in Families
Completed NCT04019041 - A Study to Evaluate the Efficacy, Safety and Tolerability of Bermekimab in Patients With Hidradenitis Suppurativa Phase 2
Completed NCT05286567 - A Double-blind Placebo-controlled Randomized Trial Evaluating the Efficacy and Safety of a Novel HSP90 Inhibitor (RGRN-305) in the Treatment of Moderate to Severe Hidradenitis Supppurativa. Phase 1
Withdrawn NCT03929835 - Study to Investigate the Efficacy and Safety of Cannabis Oil for the Treatment of Subjects With Hidradenitis Suppurativa Phase 2
Terminated NCT04325607 - Negative Pressure Wound Therapy With Instillation for Treatment of Hidradenitis Suppurativa N/A
Terminated NCT03238469 - Microwave Ablation in Mild Axillary Hidradenitis Suppurativa N/A
Completed NCT04449354 - HidraWear AX HS Study N/A
Recruiting NCT06123429 - Mindfulness in Hidradenitis Suppurativa N/A
Recruiting NCT05934825 - Clinical Trial to Evaluate Safety and Efficiency of Mesenchymal Stem Cell in Patients With Hidradenitis Suppurativa Phase 1/Phase 2
Recruiting NCT05635266 - Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Recruiting NCT06046729 - A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Phase 2
Recruiting NCT04246372 - Tofacitinib for Immune Skin Conditions in Down Syndrome Phase 2